[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed — best supported answer is B, not D.\\n\\nKey stem clues: 58-year-old man with hypertrophic obstructive cardiomyopathy (HOCM), MYH7 mutation, asymmetric septal hypertrophy, LVOT gradient 80 mmHg at rest, recurrent syncope, already on “optimal” beta‑blocker therapy yet still symptomatic. A resting gradient ≥50 mmHg with severe, drug‑refractory symptoms (especially syncope) generally meets criteria for septal reduction therapy (surgical myectomy preferred in a good surgical candidate).\\n\\nMain logical/clinical issue: The explanation asserts that disopyramide must be added before considering septal reduction. Contemporary guidelines consider addition of disopyramide reasonable but not mandatory; with severe symptoms and high gradient despite maximally tolerated beta‑blocker, referral for septal reduction is appropriate. Surgical myectomy (B) has the strongest evidence and is guideline‑preferred over alcohol ablation in many centers. Given the severity (recurrent syncope), more invasive therapy is indicated; D is no longer clearly the “most appropriate next step.”\\n\\nMain medical accuracy issue: Overstates the requirement for disopyramide before invasive therapy, making the management sequence somewhat inaccurate.\\n\\nMinimal fix: Change the key and explanation to favor B (surgical myectomy) or reduce severity (e.g., remove “recurrent syncope,” lower gradient) to make D clearly appropriate.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed — best supported answer is B, not D.\n\nKey stem clues: 58-year-old man with hypertrophic obstructive cardiomyopathy (HOCM), MYH7 mutation, asymmetric septal hypertrophy, LVOT gradient 80 mmHg at rest, recurrent syncope, already on “optimal” beta‑blocker therapy yet still symptomatic. A resting gradient ≥50 mmHg with severe, drug‑refractory symptoms (especially syncope) generally meets criteria for septal reduction therapy (surgical myectomy preferred in a good surgical candidate).\n\nMain logical/clinical issue: The explanation asserts that disopyramide must be added before considering septal reduction. Contemporary guidelines consider addition of disopyramide reasonable but not mandatory; with severe symptoms and high gradient despite maximally tolerated beta‑blocker, referral for septal reduction is appropriate. Surgical myectomy (B) has the strongest evidence and is guideline‑preferred over alcohol ablation in many centers. Given the severity (recurrent syncope), more invasive therapy is indicated; D is no longer clearly the “most appropriate next step.”\n\nMain medical accuracy issue: Overstates the requirement for disopyramide before invasive therapy, making the management sequence somewhat inaccurate.\n\nMinimal fix: Change the key and explanation to favor B (surgical myectomy) or reduce severity (e.g., remove “recurrent syncope,” lower gradient) to make D clearly appropriate.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 4-year-old boy with vesicoureteral reflux, mild hydronephrosis, recurrent UTIs, and specifically a PAX2 gene mutation. The question directly asks for the most likely associated syndrome given the mutation, not to diagnose from phenotype alone. PAX2 is classically associated with renal coloboma syndrome (papillorenal syndrome), which features renal hypoplasia/dysplasia, VUR, and optic nerve colobomas.\\nOption analysis: B (Renal coloboma syndrome) correctly matches PAX2. A (Denys-Drash) and E (Frasier) are WT1-related nephropathy/gonadal tumor syndromes. D (Alport) involves COL4A3/4/5 mutations. C (Branchio-oto-renal) is linked to EYA1 mutations. No other listed syndrome is associated with PAX2, so B is uniquely best.\\nMain logical issues: None; the mutation-gene association is explicit and discriminates clearly among choices.\\nMain medical accuracy issues: None significant; descriptions and gene associations are accurate and in line with current knowledge.\\nMinimal fix: Optionally add mention of optic nerve/ocular findings in the explanation or stem to reinforce the eponym, but no change is required for validity or accuracy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 4-year-old boy with vesicoureteral reflux, mild hydronephrosis, recurrent UTIs, and specifically a PAX2 gene mutation. The question directly asks for the most likely associated syndrome given the mutation, not to diagnose from phenotype alone. PAX2 is classically associated with renal coloboma syndrome (papillorenal syndrome), which features renal hypoplasia/dysplasia, VUR, and optic nerve colobomas.\nOption analysis: B (Renal coloboma syndrome) correctly matches PAX2. A (Denys-Drash) and E (Frasier) are WT1-related nephropathy/gonadal tumor syndromes. D (Alport) involves COL4A3/4/5 mutations. C (Branchio-oto-renal) is linked to EYA1 mutations. No other listed syndrome is associated with PAX2, so B is uniquely best.\nMain logical issues: None; the mutation-gene association is explicit and discriminates clearly among choices.\nMain medical accuracy issues: None significant; descriptions and gene associations are accurate and in line with current knowledge.\nMinimal fix: Optionally add mention of optic nerve/ocular findings in the explanation or stem to reinforce the eponym, but no change is required for validity or accuracy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 32-year-old nonpregnant woman, acute symptomatic segmental PE confirmed on CT, hemodynamically stable (no shock or hypotension described), risk factors (OCPs, family history, elevated factor VIII), no mention of cancer or severe renal disease. The question asks for most appropriate initial anticoagulant therapy.\\nDirect oral anticoagulants (e.g., rivaroxaban) are guideline-preferred first-line therapy for most stable VTE patients without contraindications. Thus option B is the best choice.\\nOption A (LMWH then warfarin) is effective but no longer preferred due to monitoring/inconvenience; appropriate alternative but not “most appropriate” per modern guidelines. Option C (UFH with thrombolysis) is for massive or high-risk PE with hemodynamic instability, not described here. Option D (fondaparinux monotherapy) is not typical first-line for PE and usually followed by an oral agent. Option E (dual antiplatelet therapy) is inappropriate for venous thromboembolism.\\nMain medical accuracy issue(s): Minor at most; the explanation appropriately notes standard indications and exclusions for DOACs.\\nMinimal fix: Explicitly state that the patient is hemodynamically stable with normal blood pressure and no signs of right heart strain, to remove any residual ambiguity about thrombolysis or UFH indications.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 32-year-old nonpregnant woman, acute symptomatic segmental PE confirmed on CT, hemodynamically stable (no shock or hypotension described), risk factors (OCPs, family history, elevated factor VIII), no mention of cancer or severe renal disease. The question asks for most appropriate initial anticoagulant therapy.\nDirect oral anticoagulants (e.g., rivaroxaban) are guideline-preferred first-line therapy for most stable VTE patients without contraindications. Thus option B is the best choice.\nOption A (LMWH then warfarin) is effective but no longer preferred due to monitoring/inconvenience; appropriate alternative but not “most appropriate” per modern guidelines. Option C (UFH with thrombolysis) is for massive or high-risk PE with hemodynamic instability, not described here. Option D (fondaparinux monotherapy) is not typical first-line for PE and usually followed by an oral agent. Option E (dual antiplatelet therapy) is inappropriate for venous thromboembolism.\nMain medical accuracy issue(s): Minor at most; the explanation appropriately notes standard indications and exclusions for DOACs.\nMinimal fix: Explicitly state that the patient is hemodynamically stable with normal blood pressure and no signs of right heart strain, to remove any residual ambiguity about thrombolysis or UFH indications.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Symmetric polyarthritis with morning stiffness (RA-like), truncal rash, poor response to methotrexate, and—critically—documented NLRP3 gene mutation. NLRP3 mutations are classically associated with cryopyrin‑associated periodic syndromes (CAPS), a group of autoinflammatory diseases featuring rash, arthritis/arthralgia, and elevated inflammatory markers. The item’s explanation explicitly anchors the teaching point to this genotype–phenotype link.\\n\\nOption B (CAPS) fits all data including the genetic mutation and atypical response to standard RA therapy. Option A (rheumatoid arthritis) is less appropriate because RA is not defined by NLRP3 mutations and would be expected at least sometimes to respond to methotrexate. Options C (adult‑onset Still’s), D (Behçet’s), and E (SLE) are not associated with NLRP3 mutations and have different classic rashes and systemic patterns.\\n\\nMain logical issue(s): None significant; the stem clearly steers toward CAPS via NLRP3.\\n\\nMain medical accuracy issue(s): Minor oversimplification—some RA patients may be MTX‑refractory—but this does not undermine the core teaching.\\n\\nMinimal fix: Clarify the autoinflammatory nature (e.g., recurrent fevers, urticarial rash) to strengthen distinction from seropositive RA, and/or specify “heterozygous gain‑of‑function NLRP3 mutation” for precision.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Symmetric polyarthritis with morning stiffness (RA-like), truncal rash, poor response to methotrexate, and—critically—documented NLRP3 gene mutation. NLRP3 mutations are classically associated with cryopyrin‑associated periodic syndromes (CAPS), a group of autoinflammatory diseases featuring rash, arthritis/arthralgia, and elevated inflammatory markers. The item’s explanation explicitly anchors the teaching point to this genotype–phenotype link.\n\nOption B (CAPS) fits all data including the genetic mutation and atypical response to standard RA therapy. Option A (rheumatoid arthritis) is less appropriate because RA is not defined by NLRP3 mutations and would be expected at least sometimes to respond to methotrexate. Options C (adult‑onset Still’s), D (Behçet’s), and E (SLE) are not associated with NLRP3 mutations and have different classic rashes and systemic patterns.\n\nMain logical issue(s): None significant; the stem clearly steers toward CAPS via NLRP3.\n\nMain medical accuracy issue(s): Minor oversimplification—some RA patients may be MTX‑refractory—but this does not undermine the core teaching.\n\nMinimal fix: Clarify the autoinflammatory nature (e.g., recurrent fevers, urticarial rash) to strengthen distinction from seropositive RA, and/or specify “heterozygous gain‑of‑function NLRP3 mutation” for precision.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: C (contradiction)\\nVerdict on keyed answer: Not defensible as written; stem is internally inconsistent\\nKey stem clues: Recurrent hypoglycemia in a type 1 diabetic; continuous nocturnal hypoglycemia; lab shows elevated proinsulin with low C‑peptide. Low C‑peptide strongly suggests exogenous insulin use; however, elevated proinsulin implies active endogenous β‑cell secretion, which conflicts with “suppressed endogenous insulin production” in the explanation and with typical factitious exogenous insulin physiology (low insulin precursors).\\nMain logical issues: The stem’s lab pattern (elevated proinsulin + low C‑peptide) is physiologically incoherent for the proposed mechanism (factitious exogenous insulin, which should suppress endogenous secretion and therefore proinsulin). The explanation misstates adrenal insufficiency (it typically causes fasting hypoglycemia, not hyperglycemia). With the contradictory lab data, no option fully matches the described mechanism; B is only partially supported by the low C‑peptide, but contradicted by high proinsulin.\\nMain medical accuracy issues: Misinterpretation of proinsulin behavior in exogenous insulin use; incorrect statement about adrenal insufficiency causing hyperglycemia.\\nMinimal fix: Change “elevated proinsulin” to “low proinsulin” (or “low/undetectable C‑peptide and proinsulin”) and correct the explanation about adrenal insufficiency to hypoglycemia, not hyperglycemia.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (contradiction)\nVerdict on keyed answer: Not defensible as written; stem is internally inconsistent\nKey stem clues: Recurrent hypoglycemia in a type 1 diabetic; continuous nocturnal hypoglycemia; lab shows elevated proinsulin with low C‑peptide. Low C‑peptide strongly suggests exogenous insulin use; however, elevated proinsulin implies active endogenous β‑cell secretion, which conflicts with “suppressed endogenous insulin production” in the explanation and with typical factitious exogenous insulin physiology (low insulin precursors).\nMain logical issues: The stem’s lab pattern (elevated proinsulin + low C‑peptide) is physiologically incoherent for the proposed mechanism (factitious exogenous insulin, which should suppress endogenous secretion and therefore proinsulin). The explanation misstates adrenal insufficiency (it typically causes fasting hypoglycemia, not hyperglycemia). With the contradictory lab data, no option fully matches the described mechanism; B is only partially supported by the low C‑peptide, but contradicted by high proinsulin.\nMain medical accuracy issues: Misinterpretation of proinsulin behavior in exogenous insulin use; incorrect statement about adrenal insufficiency causing hyperglycemia.\nMinimal fix: Change “elevated proinsulin” to “low proinsulin” (or “low/undetectable C‑peptide and proinsulin”) and correct the explanation about adrenal insufficiency to hypoglycemia, not hyperglycemia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 65-year-old man, ischemic cardiomyopathy, LVEF 25%, sustained VT, hemodynamically stable, EP study shows a reentrant circuit in infarct border zone, VT recurs despite amiodarone. This describes scar-related monomorphic VT in ischemic cardiomyopathy refractory to antiarrhythmic therapy. Current guidelines recommend catheter ablation as the next-line therapy for recurrent scar-mediated VT despite optimal medical management, especially when a defined reentry circuit is mapped.\\nOption A (catheter ablation) directly targets the arrhythmogenic substrate and matches guideline-based care. Option B (ICD upgrade to biventricular) treats dyssynchrony/heart failure, not recurrent VT itself; and ICD presence/need is not discussed. Option C (mexiletine) is sometimes adjunctive but is generally less effective and less definitive than ablation for scar VT, so not single best. Options D and E (stellate ganglionectomy / cardiac sympathetic denervation) are reserved for highly refractory VT storm when drugs and ablation fail.\\nMain medical issues: Minor—does not specify ICD status, but does not affect best next step for VT control. Minimal fix: Explicitly state the patient has an ICD already to avoid distraction from shock prevention vs rhythm control.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 65-year-old man, ischemic cardiomyopathy, LVEF 25%, sustained VT, hemodynamically stable, EP study shows a reentrant circuit in infarct border zone, VT recurs despite amiodarone. This describes scar-related monomorphic VT in ischemic cardiomyopathy refractory to antiarrhythmic therapy. Current guidelines recommend catheter ablation as the next-line therapy for recurrent scar-mediated VT despite optimal medical management, especially when a defined reentry circuit is mapped.\nOption A (catheter ablation) directly targets the arrhythmogenic substrate and matches guideline-based care. Option B (ICD upgrade to biventricular) treats dyssynchrony/heart failure, not recurrent VT itself; and ICD presence/need is not discussed. Option C (mexiletine) is sometimes adjunctive but is generally less effective and less definitive than ablation for scar VT, so not single best. Options D and E (stellate ganglionectomy / cardiac sympathetic denervation) are reserved for highly refractory VT storm when drugs and ablation fail.\nMain medical issues: Minor—does not specify ICD status, but does not affect best next step for VT control. Minimal fix: Explicitly state the patient has an ICD already to avoid distraction from shock prevention vs rhythm control.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible)\\nVerdict on keyed answer: Misleading / not defensible as best\\nKey stem clues: 8-year-old with short stature and FTT, delayed bone age, low IGF-1, normal GH stimulation test, and a mutation in IGF1R (insulin-like growth factor 1 receptor). This implies GH → liver IGF-1 production is presumably intact but there is resistance at the IGF-1 receptor level.\\nMain logical/medical issue: The explanation misinterprets IGF1R pathology. A mutation in IGF1R causes IGF-1 resistance at the receptor, not primary IGF-1 deficiency; serum IGF-1 may be normal or elevated, and receptor dysfunction would make exogenous IGF-1 replacement ineffective. Approved use of recombinant IGF-1 (mecasermin) is for severe primary IGF-1 deficiency due to GH receptor defects or GH signaling defects, not IGF1R mutations. Recombinant GH (A) could sometimes be attempted depending on specific mutation/phenotype, but evidence is limited; none of the listed options squarely matches accepted standard management of IGF1R-defect short stature. Thus no option is clearly correct according to consensus guidelines.\\nMinimal fix: Change the mutation to IGF1 gene or GH receptor (GHR) mutation while keeping low IGF-1 with normal GH, so that IGF-1 replacement (B) becomes clearly appropriate and defensible.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible)\nVerdict on keyed answer: Misleading / not defensible as best\nKey stem clues: 8-year-old with short stature and FTT, delayed bone age, low IGF-1, normal GH stimulation test, and a mutation in IGF1R (insulin-like growth factor 1 receptor). This implies GH → liver IGF-1 production is presumably intact but there is resistance at the IGF-1 receptor level.\nMain logical/medical issue: The explanation misinterprets IGF1R pathology. A mutation in IGF1R causes IGF-1 resistance at the receptor, not primary IGF-1 deficiency; serum IGF-1 may be normal or elevated, and receptor dysfunction would make exogenous IGF-1 replacement ineffective. Approved use of recombinant IGF-1 (mecasermin) is for severe primary IGF-1 deficiency due to GH receptor defects or GH signaling defects, not IGF1R mutations. Recombinant GH (A) could sometimes be attempted depending on specific mutation/phenotype, but evidence is limited; none of the listed options squarely matches accepted standard management of IGF1R-defect short stature. Thus no option is clearly correct according to consensus guidelines.\nMinimal fix: Change the mutation to IGF1 gene or GH receptor (GHR) mutation while keeping low IGF-1 with normal GH, so that IGF-1 replacement (B) becomes clearly appropriate and defensible.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 50-year-old man with acute necrotizing pancreatitis, hypotension, AKI, and very high triglycerides (1200 mg/dL). Question explicitly asks for most appropriate initial management of the hypertriglyceridemia in this acute setting. Insulin infusion (keyed answer B) is a well-accepted first-line acute therapy for hypertriglyceridemic pancreatitis as it increases lipoprotein lipase activity and rapidly lowers triglycerides. Plasmapheresis (A) is generally reserved for the most severe or refractory cases, or when there is organ failure and inadequate response/contraindication to insulin; while one could argue severity here (necrosis, hypotension, AKI), standard teaching still considers insulin the initial approach, with plasmapheresis second-line. Fibrates (C), niacin (D), and statins (E) are for chronic lipid control and not appropriate for acute triglyceride lowering in pancreatitis. No internal contradictions or missing critical data; “initial management” clearly frames acute therapy selection. Main medical issue: mild nuance that some experts may favor earlier plasmapheresis in very severe cases, but boards typically prioritize insulin first. Minimal fix: Add “he is started on IV fluids and supportive care” to clarify that systemic stabilization is underway and focus is on specific triglyceride-lowering therapy.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 50-year-old man with acute necrotizing pancreatitis, hypotension, AKI, and very high triglycerides (1200 mg/dL). Question explicitly asks for most appropriate initial management of the hypertriglyceridemia in this acute setting. Insulin infusion (keyed answer B) is a well-accepted first-line acute therapy for hypertriglyceridemic pancreatitis as it increases lipoprotein lipase activity and rapidly lowers triglycerides. Plasmapheresis (A) is generally reserved for the most severe or refractory cases, or when there is organ failure and inadequate response/contraindication to insulin; while one could argue severity here (necrosis, hypotension, AKI), standard teaching still considers insulin the initial approach, with plasmapheresis second-line. Fibrates (C), niacin (D), and statins (E) are for chronic lipid control and not appropriate for acute triglyceride lowering in pancreatitis. No internal contradictions or missing critical data; “initial management” clearly frames acute therapy selection. Main medical issue: mild nuance that some experts may favor earlier plasmapheresis in very severe cases, but boards typically prioritize insulin first. Minimal fix: Add “he is started on IV fluids and supportive care” to clarify that systemic stabilization is underway and focus is on specific triglyceride-lowering therapy.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient on infliximab (a TNF‑α inhibitor) for seropositive RA; now has systemic symptoms (fever, weight loss) and lymphadenopathy; biopsy demonstrates non‑caseating granulomas; serum ACE is elevated. These features are classic for sarcoidosis. In the context of TNF‑inhibitor therapy, a paradoxical infliximab‑induced sarcoid‑like granulomatosis is the most likely diagnosis.\\nAlternative options: Tuberculosis reactivation (A) is strongly associated with TNF inhibitors but typically shows caseating granulomas and is not supported by the biopsy description. Lymphoma (C) would not characteristically show non‑caseating granulomas plus elevated ACE. Fungal infection (D) usually yields caseating or necrotizing granulomas and would need microbiologic evidence. Amyloidosis (E) shows amyloid deposition with Congo red positivity rather than granulomas.\\nMain logical issues: None; stem provides specific pathology and lab findings that clearly point to sarcoid-like disease, and the link to infliximab is explicit.\\nMain medical accuracy issues: Minor; infliximab can cause sarcoid‑like reactions—this is accurate and contemporary.\\nMinimal fix: Clarify biopsy as “non‑caseating granulomatous inflammation with negative stains/cultures for organisms” to further distinguish from infection without changing the key.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient on infliximab (a TNF‑α inhibitor) for seropositive RA; now has systemic symptoms (fever, weight loss) and lymphadenopathy; biopsy demonstrates non‑caseating granulomas; serum ACE is elevated. These features are classic for sarcoidosis. In the context of TNF‑inhibitor therapy, a paradoxical infliximab‑induced sarcoid‑like granulomatosis is the most likely diagnosis.\nAlternative options: Tuberculosis reactivation (A) is strongly associated with TNF inhibitors but typically shows caseating granulomas and is not supported by the biopsy description. Lymphoma (C) would not characteristically show non‑caseating granulomas plus elevated ACE. Fungal infection (D) usually yields caseating or necrotizing granulomas and would need microbiologic evidence. Amyloidosis (E) shows amyloid deposition with Congo red positivity rather than granulomas.\nMain logical issues: None; stem provides specific pathology and lab findings that clearly point to sarcoid-like disease, and the link to infliximab is explicit.\nMain medical accuracy issues: Minor; infliximab can cause sarcoid‑like reactions—this is accurate and contemporary.\nMinimal fix: Clarify biopsy as “non‑caseating granulomatous inflammation with negative stains/cultures for organisms” to further distinguish from infection without changing the key.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: Persistent elevated IGF-1 after transsphenoidal surgery; patient declines further surgery; no mention of prior or failed medical therapy; question asks for “most appropriate pharmacologic therapy.” The explanation assumes resistance to somatostatin analogs, but this is not stated in the stem.\\nLogical issues: In evidence-based management of acromegaly, first-line pharmacologic therapy after unsuccessful surgery is typically a long‑acting somatostatin analog such as octreotide or lanreotide; pegvisomant is usually second line or used if somatostatin analogs fail or are not tolerated. The stem does not indicate prior use/failure of somatostatin analogs, so both octreotide (C) and pegvisomant (B) can be argued. The rationale imports an unstated condition (“resistant to … somatostatin analogs”), creating a mismatch between stem and intended key and yielding multiple defensible answers.\\nMedical accuracy: Explanation about relative potencies is broadly accurate but not aligned with typical sequencing of therapies.\\nMinimal fix: Add to stem: “Her disease remains active despite maximal doses of long‑acting octreotide” (or “a somatostatin analog”), which would clearly justify pegvisomant as the best answer.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: Persistent elevated IGF-1 after transsphenoidal surgery; patient declines further surgery; no mention of prior or failed medical therapy; question asks for “most appropriate pharmacologic therapy.” The explanation assumes resistance to somatostatin analogs, but this is not stated in the stem.\nLogical issues: In evidence-based management of acromegaly, first-line pharmacologic therapy after unsuccessful surgery is typically a long‑acting somatostatin analog such as octreotide or lanreotide; pegvisomant is usually second line or used if somatostatin analogs fail or are not tolerated. The stem does not indicate prior use/failure of somatostatin analogs, so both octreotide (C) and pegvisomant (B) can be argued. The rationale imports an unstated condition (“resistant to … somatostatin analogs”), creating a mismatch between stem and intended key and yielding multiple defensible answers.\nMedical accuracy: Explanation about relative potencies is broadly accurate but not aligned with typical sequencing of therapies.\nMinimal fix: Add to stem: “Her disease remains active despite maximal doses of long‑acting octreotide” (or “a somatostatin analog”), which would clearly justify pegvisomant as the best answer.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}]